Treatment Free Remission Assessment after Discontinuation or dose Reduction of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients
Dalia Ahmed Nafea, Ayda Aly Nazer, Mohamed H. Khalaf & Sameh Omara · International Journal of Research and Reports in Hematology · 2022
Chronic myeloid leukaemia (CML) is now more than ever the model for targeted treatment in human cancers. The success of imatinib and second-generation tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis of CML patients. Because TKI-treated CML patients have...
Open access
Research Article